Covid-19 Vaccine Corbevax

India's COVID-19 vaccine, Corbevax, has been granted an Emergency Use Listing by the World Health Organisation, the company which manufactures it in India said Hyderabad today.

Biological E. Ltd (BE) on Thursday said it has delivered 10 crore (100 million) doses of its COVID-19 vaccine, Corbevax, to the Centre so far.

The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.

Biological E's COVID-19 vaccine Corbevax has been cleared for booster shot for those 18 and above.

Pharmaceuticals firm Biological E today said it has reduced the price of its COVID-19 vaccine Corbevax to Rs 250 from Rs 840 a dose, inclusive of goods and services tax, for private vaccination centres.

The Corbevax COVID-19 vaccine for those aged 12 to 14 will cost Rs 800 in the market before taxes, sources have said. It will be sold to the government at Rs 145, the lowest in the world.

The COVID-19 vaccine to be administered to the 12-14 years age group would be Corbevax manufactured by Biological E. Limited, Hyderabad.

The Centre today released guidelines for COVID-19 vaccination of children between 12-14 years that will begin from March 16 and said only Corbevax vaccine would be used for the beneficiaries of this age group.

Members of America's influential Congressional Hispanic Caucus have urged US President Joe Biden to champion vaccine collaboration with India to bring an end to the COVID-19 pandemic.

A second COVID-19 vaccine for children has received emergency use authorisation in India. Biological E Ltd's Corbevax has got EUA for children and teens between 12 and 18 years, the vaccine-maker said in a statement today.

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million doses per month from February 2022.

The centre cleared two more vaccines today and one anti-viral drug to boost the fight against the COVID-19 pandemic. The two latest vaccines cleared by India are Corbevax and Covovax. The anti-viral drug Molnupiravir can be used during emergency.

Biological E. Limited (BE) is expecting its COVID-19 vaccine Corbevax to be rolled out by the end of November even as the city-based firm is getting ready with 100 million doses for the launch, Mahima Datla, Managing Director, BE said on Monday.

Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.

Biological E has received approval for conducting phase II/III human clinical trial of COVID-19 vaccine candidate Corbevax on children above five years and adolescents, the Department of Biotechnology said today.

India's COVID-19 vaccine, Corbevax, has been granted an Emergency Use Listing by the World Health Organisation, the company which manufactures it in India said Hyderabad today.

Biological E. Ltd (BE) on Thursday said it has delivered 10 crore (100 million) doses of its COVID-19 vaccine, Corbevax, to the Centre so far.

The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.

Biological E's COVID-19 vaccine Corbevax has been cleared for booster shot for those 18 and above.

Pharmaceuticals firm Biological E today said it has reduced the price of its COVID-19 vaccine Corbevax to Rs 250 from Rs 840 a dose, inclusive of goods and services tax, for private vaccination centres.

The Corbevax COVID-19 vaccine for those aged 12 to 14 will cost Rs 800 in the market before taxes, sources have said. It will be sold to the government at Rs 145, the lowest in the world.

The COVID-19 vaccine to be administered to the 12-14 years age group would be Corbevax manufactured by Biological E. Limited, Hyderabad.

The Centre today released guidelines for COVID-19 vaccination of children between 12-14 years that will begin from March 16 and said only Corbevax vaccine would be used for the beneficiaries of this age group.

Members of America's influential Congressional Hispanic Caucus have urged US President Joe Biden to champion vaccine collaboration with India to bring an end to the COVID-19 pandemic.

A second COVID-19 vaccine for children has received emergency use authorisation in India. Biological E Ltd's Corbevax has got EUA for children and teens between 12 and 18 years, the vaccine-maker said in a statement today.

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million doses per month from February 2022.

The centre cleared two more vaccines today and one anti-viral drug to boost the fight against the COVID-19 pandemic. The two latest vaccines cleared by India are Corbevax and Covovax. The anti-viral drug Molnupiravir can be used during emergency.

Biological E. Limited (BE) is expecting its COVID-19 vaccine Corbevax to be rolled out by the end of November even as the city-based firm is getting ready with 100 million doses for the launch, Mahima Datla, Managing Director, BE said on Monday.

Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.

Biological E has received approval for conducting phase II/III human clinical trial of COVID-19 vaccine candidate Corbevax on children above five years and adolescents, the Department of Biotechnology said today.